Among those subtypes, luminal B, HER2-positive, and TNBC high-risk early breast cancer patients (≥cT2 or lymph-node-positive) are treated using neoadjuvant chemotherapy (NAC) as the standard care. This evidence concerns the gene ERBB2 and breast cancer.